Analysts Sees Synergies and Struggles in AngioDynamics' (ANGO) Latest Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
AngioDynamics (ANGO) to Acquire Vortex Medical in $15M + Earnout Deal
October 8, 2012 4:14 PM EDTAngioDynamics, Inc. (NASDAQ: ANGO) announced today it has entered into a definitive agreement to acquire all the outstanding capital stock of Vortex Medical Inc., a privately-held company focused on the development of innovative medical devices for the removal of thrombus, or blood clots, from occluded blood vessels.
Based in Norwell, Massachusetts, Vortex is currently commercializing the AngioVac system, which includes the AngioVac Cannula and Circuit. These two disposable devices, when combined with other manufacturers' filters, pumps and return cannula, comprise an extracorporeal bypass circuit that facilitates drainage, filtration and reinfusion... More
AngioDynamics, Inc. (ANGO) Tops Q1 EPS by 1c; Lowers FY13 EPS outlook
October 8, 2012 4:07 PM EDTAngioDynamics, Inc. (NASDAQ: ANGO) reported Q1 EPS of $0.10, $0.01 better than the analyst estimate of $0.09. Revenue for the quarter came in at $83.4 million versus the consensus estimate of $84.35 million.
AngioDynamics, Inc. sees FY2013 EPS of $0.40-0.42, versus the consensus of $0.50.
For earnings history... More
